产品跳跃常常被视为原研药企阻击竞争对手仿制药企的一种战略, 从而受到反垄断的审查和规制。然而,排除那些存在制造隐患、恶意诋毁或创新骗局外,更多的产品跳跃是一种创新活动,对其严苛监管将很大程度上抑制整个行业的发展,并最终传导到消费者,降低全社会福祉。

Product hopping were often seen as a strategy forthe brand-name pharmaceutical manufacturer to ban the generic pharmaceutical company entering the market, thus it is under antitrust scrutiny and regulation. However, excluding the manufacturing defects, the malicious slander or innovation scheme, more products hopping is a kind of innovative activities, strict management to it will greatly inhibit the development of the industry, and ultimately to consumers, reduce the total social welfare.

D923

国家社科基金 战略-形象协同视角下国家知识产权形象建设研究13BGL003